Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079779850> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2079779850 endingPage "S2" @default.
- W2079779850 startingPage "S1" @default.
- W2079779850 abstract "Until 10 years ago the initial selection of anticonvulsant drug treatment was relatively straightforward. Partial seizures with or without secondary generalization were typically treated with phenytoin or carbamazepine. Phenobarbital was a second choice because of its sedating side effects. Valproate, which obtained a formal indication for partial seizure treatment in 1996, was sometimes used as a first- or second-line agent. Primarily generalized epilepsy, with either absence or myoclonic seizures or generalized tonic–clonic attacks with 3-per-second spike–wave discharges on the EEG, was typically treated with valproate. For pure absence, ethosuximide was an alternative choice, especially for young children.In the past 10 years, eight new agents for the treatment of epilepsy have been introduced to the United States market, and an additional agent, vigabatrin, has been available in Canada and Europe. Although there are subtle differences in the formal indications for each of these agents approved by the FDA and by European licensing authorities, all of them have demonstrated efficacy as adjunctive treatment of partial seizures with or without secondary generalization. Oxcarbazepine and felbamate have been approved as initial monotherapy (although felbamate is not currently used as first-line treatment), and lamotrigine has been approved for conversion to monotherapy. By contrast, none of the new agents has a formal indication for the treatment of absence and other forms of primarily generalized epilepsy, although topiramate is indicated for the treatment of generalized tonic–clonic seizures.Although FDA-approved indications are generally based on evidence obtained from randomized double-blind trials and typically guide the initial use of new therapeutic agents, they …" @default.
- W2079779850 created "2016-06-24" @default.
- W2079779850 creator A5077601092 @default.
- W2079779850 date "2004-11-22" @default.
- W2079779850 modified "2023-09-27" @default.
- W2079779850 title "Initial individualized selection of long-term anticonvulsant drugs by neurologists" @default.
- W2079779850 cites W2124847836 @default.
- W2079779850 cites W2134306772 @default.
- W2079779850 doi "https://doi.org/10.1212/wnl.63.10_suppl_4.s1" @default.
- W2079779850 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15557545" @default.
- W2079779850 hasPublicationYear "2004" @default.
- W2079779850 type Work @default.
- W2079779850 sameAs 2079779850 @default.
- W2079779850 citedByCount "1" @default.
- W2079779850 crossrefType "journal-article" @default.
- W2079779850 hasAuthorship W2079779850A5077601092 @default.
- W2079779850 hasConcept C118552586 @default.
- W2079779850 hasConcept C121332964 @default.
- W2079779850 hasConcept C154945302 @default.
- W2079779850 hasConcept C177713679 @default.
- W2079779850 hasConcept C2775858608 @default.
- W2079779850 hasConcept C2778186239 @default.
- W2079779850 hasConcept C2779253243 @default.
- W2079779850 hasConcept C2910797910 @default.
- W2079779850 hasConcept C41008148 @default.
- W2079779850 hasConcept C61797465 @default.
- W2079779850 hasConcept C62520636 @default.
- W2079779850 hasConcept C71924100 @default.
- W2079779850 hasConcept C81917197 @default.
- W2079779850 hasConcept C98274493 @default.
- W2079779850 hasConceptScore W2079779850C118552586 @default.
- W2079779850 hasConceptScore W2079779850C121332964 @default.
- W2079779850 hasConceptScore W2079779850C154945302 @default.
- W2079779850 hasConceptScore W2079779850C177713679 @default.
- W2079779850 hasConceptScore W2079779850C2775858608 @default.
- W2079779850 hasConceptScore W2079779850C2778186239 @default.
- W2079779850 hasConceptScore W2079779850C2779253243 @default.
- W2079779850 hasConceptScore W2079779850C2910797910 @default.
- W2079779850 hasConceptScore W2079779850C41008148 @default.
- W2079779850 hasConceptScore W2079779850C61797465 @default.
- W2079779850 hasConceptScore W2079779850C62520636 @default.
- W2079779850 hasConceptScore W2079779850C71924100 @default.
- W2079779850 hasConceptScore W2079779850C81917197 @default.
- W2079779850 hasConceptScore W2079779850C98274493 @default.
- W2079779850 hasIssue "Issue 10, Supplement 4" @default.
- W2079779850 hasLocation W20797798501 @default.
- W2079779850 hasLocation W20797798502 @default.
- W2079779850 hasOpenAccess W2079779850 @default.
- W2079779850 hasPrimaryLocation W20797798501 @default.
- W2079779850 hasRelatedWork W1525117012 @default.
- W2079779850 hasRelatedWork W1994561807 @default.
- W2079779850 hasRelatedWork W2042029015 @default.
- W2079779850 hasRelatedWork W2153335219 @default.
- W2079779850 hasRelatedWork W2410469042 @default.
- W2079779850 hasRelatedWork W2412930745 @default.
- W2079779850 hasRelatedWork W2429723649 @default.
- W2079779850 hasRelatedWork W2906906539 @default.
- W2079779850 hasRelatedWork W2992019836 @default.
- W2079779850 hasRelatedWork W2130993944 @default.
- W2079779850 hasVolume "63" @default.
- W2079779850 isParatext "false" @default.
- W2079779850 isRetracted "false" @default.
- W2079779850 magId "2079779850" @default.
- W2079779850 workType "article" @default.